Whitehawk Therapeutics, Inc. (WHWK) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Whitehawk Therapeutics, Inc. (WHWK) has a cash flow conversion efficiency ratio of -0.098x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-15.38 Million) by net assets ($157.17 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Whitehawk Therapeutics, Inc. (WHWK) balance sheet quality index to measure how much of total assets are equity-financed.
Whitehawk Therapeutics, Inc. - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Whitehawk Therapeutics, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check earnings quality score of Whitehawk Therapeutics, Inc. to evaluate the quality of earnings relative to operating cash generation.
Whitehawk Therapeutics, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Whitehawk Therapeutics, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Well Shin Technology Co Ltd
TW:3501
|
0.003x |
|
ChargePoint Holdings Inc
NYSE:CHPT
|
4.017x |
|
Coraza Integrated Technology Bhd
KLSE:0240
|
0.243x |
|
Astra Graphia Tbk
JK:ASGR
|
0.006x |
|
TIZIANA LIFE SCIENCES LTD
F:0RP
|
N/A |
|
Waton Financial Limited Ordinary Shares
NASDAQ:WTF
|
0.105x |
|
Den Networks Limited
NSE:DEN
|
0.015x |
|
TRUFIN PLC
F:29U
|
N/A |
Annual Cash Flow Conversion Efficiency for Whitehawk Therapeutics, Inc. (2019–2024)
The table below shows the annual cash flow conversion efficiency of Whitehawk Therapeutics, Inc. from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see WHWK market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $52.48 Million | $-59.55 Million | -1.135x | -100.08% |
| 2023-12-31 | $105.19 Million | $-59.66 Million | -0.567x | -80.96% |
| 2022-12-31 | $158.38 Million | $-49.64 Million | -0.313x | -90.67% |
| 2021-12-31 | $136.41 Million | $-22.42 Million | -0.164x | -116.09% |
| 2020-12-31 | $-12.43 Million | $-12.70 Million | 1.022x | +22.50% |
| 2019-12-31 | $-9.09 Million | $-7.58 Million | 0.834x | -- |
About Whitehawk Therapeutics, Inc.
Whitehawk Therapeutics, Inc., an oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides a three-asset antibody-drug conjugate (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in March 2025. Whitehawk Therapeutics, Inc. was incorporated in 200… Read more